Stocks › EW
Edwards Lifesciences Corp
EW·NYSE·
United States·USD
$101.85
-2.03 (-1.95%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
EW
Edwards Lifesciences Corp · NYSE
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
EWS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of EW by members of U.S. Congress · 132 on record · 13 in the last 12 months
Whale Activity
Position changes in EW reported for 2026-09-30 by 1441 institutional filers
- Increased445
- New114
- Held249
- Decreased470
- Closed94
- No prior filing69
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 58.7M | $5.07B | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 37.7M | $3.26B | increased |
| STATE STREET CORP | 26.5M | $2.29B | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 26.5M | $2.29B | increased |
| JPMORGAN CHASE & CO | 24.5M | $2.15B | increased |
| WELLINGTON MANAGEMENT GROUP LLP | 16.9M | $1.46B | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 15.6M | $1.34B | increased |
| Ninety One UK Ltd | 11.9M | $1.03B | decreased |
| Bank of New York Mellon Corp | 11.3M | $973.7M | decreased |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | 10.7M | $923.7M | decreased |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 10.2M | $879.9M | increased |
| Aristotle Capital Management, LLC | 8.1M | $700.7M | decreased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by EW insiders, by quarter · Form 4
Recent Insider Transactions
4,811 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Lippis Daniel J.CVP, TAVR | Sale | −619 | $104.25 | $65K | Nov 10, 2026 | Form 4 ↗ |
| Zovighian Bernard JCEO · Director | Sale | −9,184 | $103.39 | $949K | Nov 9, 2026 | Form 4 ↗ |
| Zovighian Bernard JCEO · Director | Sale | −13.9K | $102.78 | $1.4M | Nov 9, 2026 | Form 4 ↗ |
| BOBO DONALD E JRCVP,Strategy/Corp Development | Sale | −48.9K | $103.05 | $5.0M | Nov 9, 2026 | Form 4 ↗ |
| Lippis Daniel J.CVP, TAVR | Sale | −619 | $85.65 | $53K | Oct 8, 2026 | Form 4 ↗ |
| Markowitz WayneCVP, JAPAC | Tax withholding | −568 | $84.37 | $48K | Sep 14, 2026 | Form 4 ↗ |
| Dahl Andrew M.SVP, Corporate Controller | Tax withholding | −253 | $84.37 | $21K | Sep 13, 2026 | Form 4 ↗ |
| Markowitz WayneCVP, JAPAC | Tax withholding | −355 | $86.77 | $31K | Sep 11, 2026 | Form 4 ↗ |
| Chopra DaveenCVP, TMTT, Surgical & IHFM | Tax withholding | −398 | $86.77 | $35K | Sep 11, 2026 | Form 4 ↗ |
| Lippis Daniel J.CVP, TAVR | Sale | −619 | $87.51 | $54K | Sep 11, 2026 | Form 4 ↗ |
| Lippis Daniel J.CVP, TAVR | Option exercise | +619 | $72.68 | $45K | Sep 11, 2026 | Form 4 ↗ |
| Dahl Andrew M.SVP, Corporate Controller | Sale | −544 | $91.06 | $50K | Aug 31, 2026 | Form 4 ↗ |
| Bruls AnnetteCVP, EMEACLA | Sale | −2,644 | $89.98 | $238K | Aug 28, 2026 | Form 4 ↗ |
| Chopra DaveenCVP, TMTT, Surgical & IHFM | Sale | −30.6K | $90.99 | $2.8M | Aug 26, 2026 | Form 4 ↗ |
| Chopra DaveenCVP, TMTT, Surgical & IHFM | Sale | −1,154 | $91.76 | $106K | Aug 26, 2026 | Form 4 ↗ |
| Chopra DaveenCVP, TMTT, Surgical & IHFM | Option exercise | +31.8K | $72.68 | $2.3M | Aug 26, 2026 | Form 4 ↗ |
| Markowitz WayneCVP, JAPAC | Sale | −1,240 | $91.47 | $113K | Aug 26, 2026 | Form 4 ↗ |
| Lippis Daniel J.CVP, TAVR | Sale | −619 | $92.03 | $57K | Aug 11, 2026 | Form 4 ↗ |
| Lippis Daniel J.CVP, TAVR | Option exercise | +619 | $72.68 | $45K | Aug 11, 2026 | Form 4 ↗ |
| Markowitz WayneCVP, JAPAC | Sale | −146 | $86.03 | $13K | Jul 30, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding EW · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 18.3M | $1.65B | 0.07% | Jun 30, 2026 |
| VANGUARD 500 INDEX FUND VANGUARD INDEX FUNDS | 14.9M | $1.35B | 0.08% | Jun 30, 2026 |
| VANGUARD MID-CAP INDEX FUND VANGUARD INDEX FUNDS | 12.5M | $1.13B | 0.50% | Jun 30, 2026 |
| VANGUARD HEALTH CARE FUND VANGUARD SPECIALIZED FUNDS | 11.4M | $977.6M | 2.56% | Jul 31, 2026 |
| iShares Core S&P 500 ETF iShares Trust | 7.9M | $716.5M | 0.08% | Jun 30, 2026 |
| Fidelity 500 Index Fund Fidelity Concord Street Trust | 7.5M | $678.3M | 0.08% | Aug 31, 2026 |
| State Street(R) SPDR(R) S&P 500(R) ETF Trust | 7.0M | $631.3M | 0.08% | Jun 30, 2026 |
| VANGUARD VALUE INDEX FUND VANGUARD INDEX FUNDS | 5.5M | $495.3M | 0.19% | Jun 30, 2026 |
| VANGUARD MID-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 4.4M | $399.0M | 1.15% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF SELECT SECTOR SPDR TRUST | 4.1M | $368.0M | 0.91% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list EW's shares (CUSIP 28176E108), each fund at its latest report since Apr 22, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
No 13D/13G beneficial-ownership filings on record.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming edwards lifesciences as client
- MARSHALL & POPP, LLCEDWARDS LIFESCIENCES, LLC · 2026 Q4 · HCR, MMM, TAX, BUD—
Filing ↗ - AVENUE SOLUTIONSEDWARDS LIFESCIENCES LLC · 2026 Q3 · MMM$50K
Filing ↗ - BGR GOVERNMENT AFFAIRSEDWARDS LIFESCIENCES LLC · 2026 Q3 · HCR$50K
Filing ↗ - FARRAGUT PARTNERS LLPEDWARDS LIFESCIENCES, LLC · 2026 Q3 · MMM, HCR$50K
Filing ↗ - AKIN GUMP STRAUSS HAUER & FELDEDWARDS LIFESCIENCES LLC · 2026 Q3$60K
Filing ↗
Government Contracts
Federal awards to edwards lifesciences · USAspending
$15.1MAwarded · 296 contracts on record
- Department of Veterans AffairsCUSTOM SURGICAL IMPLANTS$68K
Oct 21, 2026 · ↗ - Department of Veterans AffairsTAVR$34K
Nov 20, 2026 · ↗ - Department of Veterans AffairsHEART VALVE CONSIGNMENT$34K
Nov 20, 2026 · ↗ - Department of Veterans AffairsHEART VALVE CONSIGNMENT$34K
Nov 20, 2026 · ↗ - Department of Veterans AffairsS3U RESILIA HEART VALVE$34K
Nov 20, 2026 · ↗ - Department of Veterans AffairsTAVR$34K
Nov 20, 2026 · ↗ - Department of Veterans AffairsIMPLANT$34K
Nov 20, 2026 · ↗ - Department of Veterans AffairsPROSTHETICS - TAVR HEART VALVES - X3$34K
Jul 8, 2025 · ↗
U.S. Patents
Recent USPTO applications naming Edwards Lifesciences Corp
No USPTO patent applications found for Edwards Lifesciences Corp.
Annual Financials
From EW's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B |
| Operating income | $1.26B | $1.38B | $1.31B | $1.50B | $1.69B |
| Net income | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B |
| Diluted EPS | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 |
| Operating cash flow | $1.60B | $542.3M | $895.8M | $1.22B | $1.73B |
| Cash and equivalents | $2.94B | $3.05B | $1.13B | $769.0M | $862.8M |
| Total assets | $13.70B | $13.06B | $9.36B | $8.29B | $8.50B |
| Total liabilities | $3.36B | $2.99B | $2.64B | $2.49B | $2.67B |
| Shareholders' equity | $10.34B | $10.00B | $6.65B | $5.81B | $5.84B |
As Edwards Lifesciences Corp tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 25, 2026 ↗
Stock Splits
Every split and reverse split in the price history
- 3-for-1Stock splitJun 1, 2020
- 2-for-1Stock splitDec 14, 2015
- 2-for-1Stock splitMay 28, 2010
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 1.01, 2.03, 9.01Material agreement · Direct financial obligationNov 19, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsNov 4, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeAug 28, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsJul 23, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteMay 8, 2026
EDGAR ↗ - 8-K · Items 5.02, 7.01Officer / director change · Reg FD disclosureMay 4, 2026
EDGAR ↗
About Edwards Lifesciences Corp
From SEC EDGAR company records
Industry (SIC 3842)Orthopedic, Prosthetic & Surgical Appliances & Supplies
SectorHealthcare
HeadquartersIRVINE, CA
IncorporatedDE
SEC CIK0001099800 ↗
Former namesCVG CONTROLLED INC







